Search

Your search keyword '"van den Dries, Carline J"' showing total 25 results
Start Over Author "van den Dries, Carline J"
25 results on '"van den Dries, Carline J"'

2. External validation of six COVID-19 prognostic models for predicting mortality risk in older populations in a hospital, primary care, and nursing home setting

Author

Zahra, Anum, van Smeden, Maarten, Abbink, Evertine J., van den Berg, Jesse M., Blom, Marieke T., van den Dries, Carline J., Gussekloo, Jacobijn, Wouters, Fenne, Joling, Karlijn J., Melis, René, Mooijaart, Simon P., Peters, Jeannette B., Polinder-Bos, Harmke A., van Raaij, Bas F.M., Appelman, Brent, la Roi-Teeuw, Hannah M., Moons, Karel G.M., and Luijken, Kim

Published
2024
Full Text
View/download PDF

3. Limited incremental predictive value of the frailty index and other vulnerability measures from routine care data for mortality risk prediction in older patients with COVID-19 in primary care

Author

HAG Trombose, Epi Methoden Team 3, Infection & Immunity, Circulatory Health, la Roi-Teeuw, Hannah M, Luijken, Kim, Blom, Marieke T, Gussekloo, Jacobijn, Mooijaart, Simon P, Polinder-Bos, Harmke A, van Smeden, Maarten, Geersing, Geert-Jan, van den Dries, Carline J, HAG Trombose, Epi Methoden Team 3, Infection & Immunity, Circulatory Health, la Roi-Teeuw, Hannah M, Luijken, Kim, Blom, Marieke T, Gussekloo, Jacobijn, Mooijaart, Simon P, Polinder-Bos, Harmke A, van Smeden, Maarten, Geersing, Geert-Jan, and van den Dries, Carline J

Published
2024

4. Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial

Author

Trinks-Roerdink, Emmy M., primary, Geersing, Geert-Jan, additional, van den Dries, Carline J., additional, Hemels, Martin E. W., additional, Rienstra, Michiel, additional, van Gelder, Isabelle C., additional, van Smeden, Maarten, additional, van Klaveren, David, additional, Kent, David M., additional, Rutten, Frans H., additional, and van Doorn, Sander, additional

Published
2023
Full Text
View/download PDF

5. Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Author

van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, van Doorn, Sander, Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, and Biomolecular Mass Spectrometry and Proteomics

Subjects
Pharmacology, Anticoagulation, non-vitamin K antagonist oral anticoagulants, Pharmacology (medical), Off-label dose reduction, Atrial fibrillation
Abstract

Aim: To investigate the effects of off-label non-vitamin K oral anticoagulant (NOAC) dose reduction compared with on-label standard dosing in atrial fibrillation (AF) patients in routine care. Methods: Population-based cohort study using data from the United Kingdom Clinical Practice Research Datalink, comparing adults with non-valvular AF receiving an off-label reduced NOAC dose to patients receiving an on-label standard dose. Outcomes were ischaemic stroke, major/non-major bleeding and mortality. Inverse probability of treatment weighting and inverse probability of censoring weighting on the propensity score were applied to adjust for confounding and informative censoring. Results: Off-label dose reduction occurred in 2466 patients (8.0%), compared with 18 108 (58.5%) on-label standard-dose users. Median age was 80 years (interquartile range [IQR] 73.0-86.0) versus 72 years (IQR 66-78), respectively. Incidence rates were higher in the off-label dose reduction group compared to the on-label standard dose group, for ischaemic stroke (0.94 vs 0.70 per 100 person years), major bleeding (1.48 vs 0.83), non-major bleeding (6.78 vs 6.16) and mortality (10.12 vs 3.72). Adjusted analyses resulted in a hazard ratio of 0.95 (95% confidence interval [CI] 0.57-1.60) for ischaemic stroke, 0.88 (95% CI 0.57-1.35) for major bleeding, 0.81 (95% CI 0.67-0.98) for non-major bleeding and 1.34 (95% CI 1.12-1.61) for mortality. Conclusion: In this large population-based study, the hazards for ischaemic stroke and major bleeding were low, and similar in AF patients receiving an off-label reduced NOAC dose compared with on-label standard dose users, while non-major bleeding risk appeared to be lower and mortality risk higher. Caution towards prescribing an off-label reduced NOAC dose is therefore required.

Published
2022
Full Text
View/download PDF

6. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis

Author

Joosten, Linda P T, primary, van Maanen, Rosanne, additional, van den Dries, Carline J, additional, Rutten, Frans H, additional, Hoes, Arno W, additional, Granger, Christopher B, additional, Hemels, Martin E W, additional, Geersing, Geert-Jan, additional, and van Doorn, Sander, additional

Published
2023
Full Text
View/download PDF

7. Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial

Author

Trinks-Roerdink, Emmy M., Geersing, Geert Jan, van den Dries, Carline J., Hemels, Martin E.W., Rienstra, Michiel, van Gelder, Isabelle C., van Smeden, Maarten, van Klaveren, David, Kent, David M., Rutten, Frans H., van Doorn, Sander, Trinks-Roerdink, Emmy M., Geersing, Geert Jan, van den Dries, Carline J., Hemels, Martin E.W., Rienstra, Michiel, van Gelder, Isabelle C., van Smeden, Maarten, van Klaveren, David, Kent, David M., Rutten, Frans H., and van Doorn, Sander

Abstract

Introduction:Integrated care is effective in reducing all-cause mortality in patients with atrial fibrillation (AF) in primary care, though time and resource intensive. The aim of the current study was to assess whether integrated care should be directed at all AF patients equally. Methods:The ALL-IN trial (n = 1,240 patients, median age 77 years) was a cluster-randomized trial in which primary care practices were randomized to provide integrated care or usual care to AF patients aged 65 years and older. Integrated care comprised of (i) anticoagulation monitoring, (ii) quarterly checkups and (iii) easy-access consultation with cardiologists. For the current analysis, cox proportional hazard analysis with all clinical variables from the CHA2DS2-VASc score was used to predict all-cause mortality in the ALL-IN trial. Subsequently, the hazard ratio and absolute risk reduction were plotted as a function of this predicted mortality risk to explore treatment heterogeneity. Results:Under usual care, after a median of 2 years follow-up the absolute risk of all-cause mortality in the highest-risk quarter was 31.0%, compared to 4.6% in the lowest-risk quarter. On the relative scale, there was no evidence of treatment heterogeneity (p for interaction = 0.90). However, there was substantial treatment heterogeneity on the absolute scale: risk reduction in the lowest risk- quarter of risk 3.3% (95% CI -0.4% - 7.0) compared to 12.0% (95% CI 2.7% - 22.0) in the highest risk quarter. Conclusion:While the relative degree of benefit from integrated AF care is similar in all patients, patients with a high all-cause mortality risk have a greater benefit on an absolute scale and should therefore be prioritized when implementing integrated care.

Published
2023

8. Managing the Increasing Burden of Atrial Fibrillation through Integrated Care in Primary Care: A Cost-Effectiveness Analysis

Author

Circulatory Health, HAG Trombose, HEE, Child Health, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, Epi Methoden, Cancer, van den Dries, Carline J, van der Meulen, Miriam P, Frederix, Geert W J, Hoes, Arno W, Moons, Karel G M, Geersing, Geert-Jan, Circulatory Health, HAG Trombose, HEE, Child Health, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, Epi Methoden, Cancer, van den Dries, Carline J, van der Meulen, Miriam P, Frederix, Geert W J, Hoes, Arno W, Moons, Karel G M, and Geersing, Geert-Jan

Published
2023

9. Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial

Author

HAG Trombose, Circulatory Health, Epi Methoden Team 3, Infection & Immunity, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Trinks-Roerdink, Emmy M, Geersing, Geert-Jan, van den Dries, Carline J, Hemels, Martin E W, Rienstra, Michiel, van Gelder, Isabelle C, van Smeden, Maarten, van Klaveren, David, Kent, David M, Rutten, Frans H, van Doorn, Sander, HAG Trombose, Circulatory Health, Epi Methoden Team 3, Infection & Immunity, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Trinks-Roerdink, Emmy M, Geersing, Geert-Jan, van den Dries, Carline J, Hemels, Martin E W, Rienstra, Michiel, van Gelder, Isabelle C, van Smeden, Maarten, van Klaveren, David, Kent, David M, Rutten, Frans H, and van Doorn, Sander

Published
2023

10. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis

Author

HAG Trombose, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Directie Raad van Bestuur, Joosten, Linda P T, van Maanen, Rosanne, van den Dries, Carline J, Rutten, Frans H, Hoes, Arno W, Granger, Christopher B, Hemels, Martin E W, Geersing, Geert-Jan, van Doorn, Sander, HAG Trombose, Circulatory Health, HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Directie Raad van Bestuur, Joosten, Linda P T, van Maanen, Rosanne, van den Dries, Carline J, Rutten, Frans H, Hoes, Arno W, Granger, Christopher B, Hemels, Martin E W, Geersing, Geert-Jan, and van Doorn, Sander

Published
2023

11. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Author

Circulatory Health, HAG Trombose, Epi Methoden, Cancer, JC onderzoeksprogramma Methodology, Directie Raad van Bestuur, JC onderzoeksprogramma Cardiovascular Health, van den Dries, Carline J, Pajouheshnia, Romin, van den Ham, Hendrika A, Souverein, Patrick, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, van Doorn, Sander, Circulatory Health, HAG Trombose, Epi Methoden, Cancer, JC onderzoeksprogramma Methodology, Directie Raad van Bestuur, JC onderzoeksprogramma Cardiovascular Health, van den Dries, Carline J, Pajouheshnia, Romin, van den Ham, Hendrika A, Souverein, Patrick, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, and van Doorn, Sander

Published
2023

13. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Author

Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, Biomolecular Mass Spectrometry and Proteomics, van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, van Doorn, Sander, Afd Pharmacoepi & Clinical Pharmacology, Sub Biomol.Mass Spectrometry & Proteom., Pharmacoepidemiology and Clinical Pharmacology, Biomolecular Mass Spectrometry and Proteomics, van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, and van Doorn, Sander

Published
2022

14. Managing the Increasing Burden of Atrial Fibrillation through Integrated Care in Primary Care: A CostEffectiveness Analysis.

Author

VAN DEN DRIES, CARLINE J., VAN DER MEULEN, MIRIAM P., FREDERIX, GEERT W. J., HOES, ARNO W., MOONS, KAREL G. M., and GEERSING, GEERT-JAN

Subjects
*ATRIAL fibrillation treatment, *PRIMARY health care, *COST effectiveness, *DESCRIPTIVE statistics, *QUESTIONNAIRES, *RESEARCH funding, *INTEGRATED health care delivery, *DATA analysis software, *QUALITY-adjusted life years
Abstract

Introduction: Integrated care for patients with atrial fibrillation (AF) in primary care reduced mortality compared to usual care. We assessed the cost-effectiveness of this approach. Methods: Dutch primary care practices were randomised to provide integrated care for AF patients or usual care. A cost-effectiveness analysis was performed from a societal perspective with a 2-year time horizon to estimate incremental costs and Quality Adjusted Life Years (QALYs). A sensitivity analysis was performed, imputing missing questionnaires for a large group of usual care patients. Results: 522 patients from 15 intervention practices were compared to 425 patients from 11 usual care practices. No effect on QALYs was seen, while mean costs indicated a cost reduction between €865 (95% percentile interval (PI) –€5730 to €3641) and €1343 (95% PI –€6534 to €3109) per patient per 2 years. The cost-effectiveness probability ranged between 36% and 54%. In the sensitivity analysis, this increased to 95%-99%. Discussion: Results should be interpreted with caution due to missing information for a large proportion of usual care patients. Conclusion: The higher costs from extra primary care consultations were likely outweighed by cost reductions for other resources, yet this study doesn’t give sufficient clarity on the cost-effectiveness of integrated AF care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Author

van den Dries, Carline J., Pajouheshnia, Romin, van den Ham, Hendrika A., Souverein, Patrick, Moons, Karel G. M., Hoes, Arno W., Geersing, Geert‐Jan, and van Doorn, Sander

Subjects
APIXABAN, ATRIAL fibrillation, ORAL medication, ISCHEMIC stroke, MEDICAL research, CONFIDENCE intervals
Abstract

Aim: To investigate the effects of off‐label non‐vitamin K oral anticoagulant (NOAC) dose reduction compared with on‐label standard dosing in atrial fibrillation (AF) patients in routine care. Methods: Population‐based cohort study using data from the United Kingdom Clinical Practice Research Datalink, comparing adults with non‐valvular AF receiving an off‐label reduced NOAC dose to patients receiving an on‐label standard dose. Outcomes were ischaemic stroke, major/non‐major bleeding and mortality. Inverse probability of treatment weighting and inverse probability of censoring weighting on the propensity score were applied to adjust for confounding and informative censoring. Results: Off‐label dose reduction occurred in 2466 patients (8.0%), compared with 18 108 (58.5%) on‐label standard‐dose users. Median age was 80 years (interquartile range [IQR] 73.0‐86.0) versus 72 years (IQR 66‐78), respectively. Incidence rates were higher in the off‐label dose reduction group compared to the on‐label standard dose group, for ischaemic stroke (0.94 vs 0.70 per 100 person years), major bleeding (1.48 vs 0.83), non‐major bleeding (6.78 vs 6.16) and mortality (10.12 vs 3.72). Adjusted analyses resulted in a hazard ratio of 0.95 (95% confidence interval [CI] 0.57‐1.60) for ischaemic stroke, 0.88 (95% CI 0.57‐1.35) for major bleeding, 0.81 (95% CI 0.67‐0.98) for non‐major bleeding and 1.34 (95% CI 1.12‐1.61) for mortality. Conclusion: In this large population‐based study, the hazards for ischaemic stroke and major bleeding were low, and similar in AF patients receiving an off‐label reduced NOAC dose compared with on‐label standard dose users, while non‐major bleeding risk appeared to be lower and mortality risk higher. Caution towards prescribing an off‐label reduced NOAC dose is therefore required. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation

Author

van den Dries, Carline J, van Doorn, Sander, Souverein, Patrick, Pajouheshnia, Romin, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, van den Ham, Hendrika A, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Risk of mortality, medicine, atrial fibrillation, 030212 general & internal medicine, polypharmacy, anticoagulation, Stroke, Polypharmacy, business.industry, Hazard ratio, medicine.disease, Concomitant drug, lcsh:RC666-701, major bleeding, Concomitant, Relative risk, Apixaban, Original Article, business, effect modification, medicine.drug
Abstract

Background The benefit of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) on major bleeding was less prominent among atrial fibrillation (AF) patients with polypharmacy in post-hoc randomized controlled trials analyses. Whether this phenomenon also exists in routine care is unknown. The aim of the study is to investigate whether the number of concomitant drugs prescribed modifies safety and effectiveness of DOACs compared with VKAs in AF patients treated in general practice. Study Design Adult, nonvalvular AF patients with a first DOAC or VKA prescription between January 2010 and July 2018 were included, using data from the United Kingdom Clinical Practice Research Datalink. Primary outcome was major bleeding, secondary outcomes included types of major bleeding, nonmajor bleeding, ischemic stroke, and all-cause mortality. Effect modification was assessed using Cox proportional hazard regression, stratified for the number of concomitant drugs into three strata (0–5, 6–8, ≥9 drugs), and by including the continuous variable in an interaction term with the exposure (DOAC vs. VKA). Results A total of 63,600 patients with 146,059 person-years of follow-up were analyzed (39,840 person-years of DOAC follow-up). The median age was 76 years in both groups, the median number of concomitant drugs prescribed was 7. Overall, the hazard of major bleeding was similar between VKA-users and DOAC-users (hazard ratio [HR] 0.98; 95% confidence interval [CI] 0.87–1.11), though for apixaban a reduction in major bleeding was observed (HR 0.81; 95% CI 0.68–0.98). Risk of stroke was comparable, while risk of nonmajor bleeding was lower in DOAC users compared with VKA users (HR 0.92; 95% CI 0.88–0.97). We did not observe any evidence for an impact of polypharmacy on the relative risk of major bleeding between VKA and DOAC across our predefined three strata of concomitant drug use (p-value for interaction = 0.65). For mortality, however, risk of mortality was highest among DOAC users, increasing with polypharmacy and independent of the type of DOAC prescribed (p-value for interaction Conclusion In this large observational, population-wide study of AF patients, risk of bleeding, and ischemic stroke were comparable between DOACs and VKAs, irrespective of the number of concomitant drugs prescribed. In AF patients with increasing polypharmacy, our data appeared to suggest an unexplained yet increased risk of mortality in DOAC-treated patients, compared with VKA recipients.

Published
2020

17. Integrale zorg voor patiënten met atriumfibrilleren: Is toepassing in de huisartsenpraktijk veilig?

Author

HAG Trombose, Circulatory Health, Other research (not in main researchprogram), JC onderzoeksprogramma Cardiovasculaire Epidemiologie, HAG Hart- Vaatziekten, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, Van den Dries, Carline J., Van Doorn, Sander, Rutten, Frans H., Oudega, Ruud, Van de Leur, Sjef J.C.M., Elvan, Arif, Grave, Lisa Oude, Bilo, Henk J.G., Moons, Karel G.M., Hoes, Arno W., Geersing, Geert Jan, HAG Trombose, Circulatory Health, Other research (not in main researchprogram), JC onderzoeksprogramma Cardiovasculaire Epidemiologie, HAG Hart- Vaatziekten, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, Van den Dries, Carline J., Van Doorn, Sander, Rutten, Frans H., Oudega, Ruud, Van de Leur, Sjef J.C.M., Elvan, Arif, Grave, Lisa Oude, Bilo, Henk J.G., Moons, Karel G.M., Hoes, Arno W., and Geersing, Geert Jan

Published
2021

19. The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van den Dries, Carline J, van Doorn, Sander, Souverein, Patrick, Pajouheshnia, Romin, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, van den Ham, Hendrika A, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, van den Dries, Carline J, van Doorn, Sander, Souverein, Patrick, Pajouheshnia, Romin, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, and van den Ham, Hendrika A

Published
2020

20. The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation

Author

HAG Trombose, Circulatory Health, Other research (not in main researchprogram), JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Epi Methoden Team 1, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, van den Dries, Carline J, van Doorn, Sander, Souverein, Patrick, Pajouheshnia, Romin, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, van den Ham, Hendrika A, HAG Trombose, Circulatory Health, Other research (not in main researchprogram), JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Epi Methoden Team 1, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Directie Raad van Bestuur, van den Dries, Carline J, van Doorn, Sander, Souverein, Patrick, Pajouheshnia, Romin, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, and van den Ham, Hendrika A

Published
2020

21. Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial

Author

HAG Trombose, Other research (not in main researchprogram), JC onderzoeksprogramma Cardiovascular Health, HAG Hart- Vaatziekten, Circulatory Health, Epi Methoden, Cancer, JC onderzoeksprogramma Methodology, Directie Raad van Bestuur, van den Dries, Carline J, van Doorn, Sander, Rutten, Frans H, Oudega, Ruud, van de Leur, Sjef J C M, Elvan, Arif, Oude Grave, Lisa, Bilo, Henk J G, Moons, Karel G M, Hoes, Arno W, Geersing, Geert-Jan, HAG Trombose, Other research (not in main researchprogram), JC onderzoeksprogramma Cardiovascular Health, HAG Hart- Vaatziekten, Circulatory Health, Epi Methoden, Cancer, JC onderzoeksprogramma Methodology, Directie Raad van Bestuur, van den Dries, Carline J, van Doorn, Sander, Rutten, Frans H, Oudega, Ruud, van de Leur, Sjef J C M, Elvan, Arif, Oude Grave, Lisa, Bilo, Henk J G, Moons, Karel G M, Hoes, Arno W, and Geersing, Geert-Jan

Published
2020

23. Integrated management of atrial fibrillation including tailoring of anticoagulation in primary care : Study design of the ALL-IN cluster randomised trial

Author

Van Den Dries, Carline J., Oudega, Ruud, Elvan, Arif, Rutten, Frans H., van de Leur, Sjef J C M, Bilo, Henk J. G., Hoes, Arno W., Moons, Karel G.M., Geersing, Geert Jan, Van Den Dries, Carline J., Oudega, Ruud, Elvan, Arif, Rutten, Frans H., van de Leur, Sjef J C M, Bilo, Henk J. G., Hoes, Arno W., Moons, Karel G.M., and Geersing, Geert Jan

Published
2017

24. Integrated management of atrial fibrillation including tailoring of anticoagulation in primary care: Study design of the ALL-IN cluster randomised trial

Author

Epi Infectieziekten Team 3, UMC Utrecht, Other research (not in main researchprogram), HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Circulatory Health, General Practice & Nursing Science, Epi Methoden, Child Health, Cancer, JC onderzoeksprogramma Methodologie, Van Den Dries, Carline J., Oudega, Ruud, Elvan, Arif, Rutten, Frans H., van de Leur, Sjef J C M, Bilo, Henk J. G., Hoes, Arno W., Moons, Karel G.M., Geersing, Geert Jan, Epi Infectieziekten Team 3, UMC Utrecht, Other research (not in main researchprogram), HAG Hart- Vaatziekten, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Circulatory Health, General Practice & Nursing Science, Epi Methoden, Child Health, Cancer, JC onderzoeksprogramma Methodologie, Van Den Dries, Carline J., Oudega, Ruud, Elvan, Arif, Rutten, Frans H., van de Leur, Sjef J C M, Bilo, Henk J. G., Hoes, Arno W., Moons, Karel G.M., and Geersing, Geert Jan

Published
2017

25. Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults

Author

van Bunderen, Christa C, primary, van den Dries, Carline J, additional, Heymans, Martijn W, additional, Franken, Anton A M, additional, Koppeschaar, Hans P F, additional, van der Lely, Aart J, additional, and Drent, Madeleine L, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results